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Summary
Background: Patients with Duchenne muscular dystrophy (DMD) often have severe
heart failure with a high mortality rate. Most DMD patients with cardiomyopathy
became symptomatic in their early to middle teens and usually die of congestive
heart failure within 2—3 years from the onset of symptoms. It has been reported that
the combination of an angiotensin-converting enzyme (ACE) inhibitor and a beta-
blocker has additive beneﬁts in patients with heart failure. The aim of this study
was to assess whether the combination of an ACE inhibitor and a beta-blocker is asso-
ciated with long-term survival of DMD patients with left ventricular (LV) dysfunction.
Methods: We retrospectively analyzed the outcomes of 52 DMD patients who had
begun treatment for heart failure with an ACE inhibitor and a beta-blocker at
National Yakumo Hospital during the period from 1992 to 2005. All patients used
wheelchairs in their daily lives. Patients were classiﬁed as symptomatic or asymp-
tomatic at the initiation of treatment with these two drugs. Twelve patients who
had already had apparent symptoms due to heart failure were enrolled in a treat-
ment group. Forty patients who had no symptoms with reduced LV ejection fraction
(≤45% in echocardiography) were enrolled in a prevention group.
Results: Five-year and 7-year survival rates of all patients were 93 and 84%, respec-
tively. In the treatment group, 5-year and 7-year survival rate were 81 and 71%,
respectively. Survival rate became zero at 10.9 years. In the prevention group, 5-year
and 7-year survival rates were 97 and 84%, respectively, and 10-year survival rate
was 72%. Nine patients in the prevention group remained event-free over 10 years.
∗ Corresponding author. Tel.: +81 137 63 2126; fax: +81 137 64 2715.
E-mail address: hogata@seagreen.ocn.ne.jp (H. Ogata).
0914-5087/$ — see front matter © 2008 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights reserved.
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Conclusions: In this study, the combination of an ACE inhibitor and a beta-blocker
had a beneﬁcial effect on long-term survival of DMD patients with heart failure. The
treatment was particularly effective for asymptomatic patients with LV dysfunction.
e of Cardiology. Published by Elsevier Ireland Ltd. All rights
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arthralgias, chills, decreased urinary output, irri-
tability, and difﬁculty in concentration [16]. The
prevention group included patients who had no© 2008 Japanese Colleg
reserved.
ntroduction
uchenne muscular dystrophy (DMD) is an X-linked
ecessive disorder occurring in one in 3500 male
irths. DMD is caused by mutations in the dys-
rophin gene that result in marked reduction or
bsence of the sarcolemnal protein dystrophin.
atients with DMD are characterized by progressive
keletal muscle wasting and become wheelchair-
ound before 13 years of age [1]. Patients managed
onventionally rarely survive beyond their teens
ecause of respiratory and heart failure. Cardiomy-
pathy in most DMD patients is similar clinically
o dilated cardiomyopathy (DCM). DMD is often
omplicated by severe heart failure and has a
ery high mortality rate. Severe heart failure
ccurs in DMD patients from their early teens
nd is very common in patients over 18 years
f age [2,3]. Several studies have indicated that
pproximately 10—15% of patients with DMD die
rom cardiac failure caused by DCM [3,4]. Most
atients with DMD remain asymptomatic for many
ears in spite of the progression of cardiac dys-
unction, because their energy expenditure and
xygen consumption are severely curtailed by mus-
le weakness. Patients with DMD might therefore
ave severe cardiac dysfunction when they ini-
ially experience cardiac symptoms. Non-invasive
entilation (NIV) has improved the rate of sur-
ival to 25 years from 0 to 53%. Nevertheless,
he mean age of survival in the presence of car-
iomyopathy has been reported to be 16.9 years
5]. It is known that combination therapy with
n angiotensin-converting enzyme (ACE) inhibitor
nd a beta-adrenergic blocking agent improve
he survival of patients with left ventricular (LV)
ysfunction [6—15]. However, the beneﬁt of beta-
lockers and ACE inhibitors for long-term survival
f DMD patients with heart failure is not clear.
n ACE inhibitor and a beta-blocker began to be
sed from 1992 in DMD patients with heart failure
hose treatment was managed at National Yakumo
ospital. At that time, both of the drugs were
rescribed when symptoms of heart failure were
pparent. We often experienced rapid worsening
f heart failure in DMD patients. We tried to begin
he treatment with an ACE inhibitor and a beta-
a
t
b
blocker when LV dysfunction was diagnosed even
f patients had no symptoms. The purpose of this
tudy was to assess the effects of therapy with a
eta-blocker and an ACE inhibitor on survival rate
n DMD patients with heart failure and to determine
he efﬁcacy of the combination therapy in asymp-
omatic patients.
ethods
tudy patients
e reviewed the records for 56 patients diagnosed
ith DMD who were diagnosed with LV dysfunction
nd had begun treatment for heart failure with
n ACE inhibitor and a beta-blocker at National
akumo Hospital during the period from 1992 to
005. Two patients who did not have routine follow-
p at National Yakumo Hospital were excluded.
nother two patients whose diagnosis was sug-
estive of an intermediate or Becker muscular
ystrophy, because they walked over the age of
3 years, were also excluded. Fifty-two consecu-
ive patients with DMD were enrolled in this study.
n all patients, diagnosis of DMD was conﬁrmed
ither by DNA analysis that revealed deletion of
xons in the dystrophin gene or by muscle biopsy
hat showed the absence of dystrophin. All of
he patients used wheelchairs in their daily lives.
he patients were classiﬁed as symptomatic or
symptomatic when they begun the treatment with
n ACE inhibitor and a beta-blocker and were
nrolled in a treatment or a prevention group.
he treatment group included patients who had
lready had apparent symptoms due to heart fail-
re when they had begun treatment with these
wo drugs despite their wheelchair dependence.
heir symptoms included cough, fatigue, palpita-
ions, sweating, chest and abdominal discomfort,pparent symptoms with reduced LV ejection frac-
ion (LVEF, ≤45% in echocardiography) at the
eginning of treatment with an ACE inhibitor and a
eta-blocker.
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Table 1 Baseline characteristics.
Characteristic Patients with DMD
n = 52
Age at starting treatment
(years)
19.5± 5.8
Duration (years) 6.9± 3.3
NIV use 37 (71%)
Past history of pulmonary
congestion
8 (15%)
Echocardiographic measurements
LVDd (mm) 58± 9
FS (%) 16± 5
LVEF (%) 36± 8
BNP (pg/ml) 135± 277
Treatment dose per day for maintenance (mg)
ACE inhibitors
Enalapril 39 (75%) 3.7± 1.8
Lisinopril 7 (13%) 6.1± 4.3
Others 6 (12%)
Beta-blockers
Bisoprolol 43 (83%) 3.± 1.3
Metoprolol 7 (13%) 20.8± 2.0
Carvedilol 2 (4%) 10± 0
Diuretics 38 (73%)
Digoxin 49 (94%)
DMD: Duchenne muscular dystrophy; ACE: angiotension-
converting enzyme; NIV: non-invasive ventilation; LVDd: left
ventricular end-diastolic diameter; FS: fractional shortening;
LVEF: left ventricular ejection fraction; BNP: brain natri-
uretic peptide.
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Patients were administered a beta-blocker
within 3 months after starting treatment with
an ACE inhibitor. Doses of both drugs reached
maintenance doses within 3 months after start-
ing administration. Echocardiography had been
routinely performed once or twice a year. Echocar-
diographic variables were determined according to
the standards of the American Society of Echocar-
diography.
End points
All-cause mortality was used as the primary end
point in this study. For the present analysis,
deaths due to pump failure include deaths due to
‘‘worsening heart failure with or without arrhyth-
mia’’; arrhythmic deaths include only deaths due
to ‘‘arrhythmia without worsening heart failure’’
[13]. Mortality was censored on 31 December 2005.
Statistical analysis
Data are expressed as means± S.D. Chi-square
analysis was used for categorical variables. Paired
or unpaired t tests were used for evaluation
of differences between the two groups. Differ-
ences were regarded as statistically signiﬁcant at
P < 0.05. Outcomes were assessed by Kaplan—Meier
survival analysis and log-rank test statistics.
Variables included in the univariate analysis for
the prevention group were age, LV end-diastolic
diameter (LVDd), LV fractional shortening (%FS),
LVEF, and plasma brain natriuretic peptide (BNP)
level at the start of treatment.
Results
Patient population
Characteristics of the 52 patients are shown in
Table 1. Thirty-eight (70%) of the 52 patients
used ventilators in their daily lives. Eight (15%) of
the 52 patients had a past history of pulmonary
edema. Most of the patients (83%) received biso-
prolol as a beta-blocker, and 4% of the patients
received carvedilol. The mean follow-up period
was 6.8± 3.2 years.
Actuarial survival for all patientsPatients taking both an ACE inhibitor and a beta-
blocker could achieve long-term survival. The
5-year survival rate for all 52 patients was 93% and
the 7-year survival rate was 84% (Fig. 1). Eleven
patients survived for more than 10 years.
m
f
r
l
migure 1 Kaplan—Meier survival curve for all patients
reated with a beta-blocker and an ACE inhibitor.
reatment and prevention groups
atients were classiﬁed as symptomatic (n = 12,
3%) or asymptomatic (n = 40, 77%) at the start
f therapy and enrolled in the treatment or the
revention group (Table 2). Patients in the treat-
ent and the prevention groups were followedor an average of 7.1± 3.4 and 6.7± 3.2 years,
espectively. LVDd was large and contractility of the
eft ventricle decreased signiﬁcantly in the treat-
ent group compared with those in the prevention
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Table 2 Basic characteristics of study groups.
Characteristic Treatment n = 12 Prevention n = 40 P-value
Age at starting treatment (years) 17.6± 3.8 20.1± 6.3 NS
Duration (years) 7.1± 3.4 6.7± 3.2 NS
NIV use 8 (67%) 29 (73%) NS
Echocardiographic measurements
LVDd (mm) 67± 6 56± 7 <0.001
FS (%) 11± 5 18± 4 <0.001
LVEF (%) 28± 8 38± 7 <0.001
BNP (pg/ml) 474± 468 42± 47 <0.05
Treatment
Beta-blockers
Bisoprolol 12 (100%) 31 (78%)
Dose per day for maintenance (mg) 3.0± 1.0 3.2± 1.4 NS
Metoprolol 0 7(18%)
Dose per day for maintenance (mg) 20.8± 2.0
Carvedilol 0 2(4%)
Dose per day for maintenance (mg) 10.0± 0
ACE inhibitors
Enalapril 8 (67%) 31(78%)
Dose per day for maintenance (mg) 2.6± 1.2 4.0± 1.8 <0.05
Lisinopril 3 (25%) 4 (10%)
Dose per day for maintenance (mg) 7.5± 6.7 5.0± 2.0 NS
Others 1 (8%) 5(12%)
Diuretics 12 (100%) 37 (88%) NS
(100%) 26 (62%) <0.05
ting enzyme; NIV: non-invasive ventilation; LVDd: left ventricular
ntricular ejection fraction; BNP: brain natriuretic peptide.
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Predictors of long-term survival in
asymptomatic patients
In this study, univariate analysis revealed that only
%FS was a signiﬁcant predictor of long-term sur-
vival for patients in the prevention group (P < 0.05).
The patients in the prevention group were stratiﬁedDigoxin 12
DMD: Duchenne muscular dystrophy; ACE: angiotensin-conver
end-diastolic diameter; FS: fractional shortening; LVEF: left ve
roup. All patients in the treatment group received
iuretics.
ctuarial survival for patients in the two
roups
rognosis was improved remarkably in both the
reatment group and prevention group (Fig. 2).
n the treatment group, 5-year survival rate was
1% and 7-year survival rate was 71%. Survival rate
ecame zero at 10.9 years. In the prevention group,
-year survival rate was 97% and 7-year survival rate
as 84%. Furthermore, 10-year survival rate was
2% in the prevention group. Patients in the pre-
ention group tended to have better survival than
atients in the treatment group (P < 0.001 by log-
ank test). Nine patients in the prevention group
emained event-free over 10 years.odes of death
atients in the prevention group were less likely
o die than were patients in the treatment group
Table 3). Three patients in the prevention group
ied of apparent cardiac events.
Figure 2 Kaplan—Meier survival curve for study groups.
Patients in the prevention group are represented by the
solid line, those in the treatment group by the dotted
gray line.
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Table 3 Modes of death.
Treatment group (n = 12)
All-cause mortality 58%
(7 patients)
Number of patients
Arrhythmia with
worsening heart
failure
4
Worsening heart failure 1
Respiratory
complication
2
Prevention group (n = 40)
All-cause mortality 15%
(6 patients)
Number of patients
Arrhythmia with
worsening heart
failure
2
Arrhythmia without
worsening heart
failure
1
Respiratory
complication
1
Unknown 2
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years. It is therefore possible that treatment withFigure 3 Kaplan—Meier survival curve for 40 patients in
the prevention group subdivided into two groups accord-
ing to the median %FS (19%). %FS: %fractional shortening.
into two groups based on median %FS (19%) at the
start of treatment and a cumulative survival curve
was constructed according to Kaplan—Meiyer sur-
vival methods. Long-term survival of patients with
%FS > 19% tended to be better than that of patients
with %FS < 19%, but the difference was not statisti-
cally signiﬁcant (Fig. 3).Discussion
The present study demonstrated that the com-
bination of an ACE inhibitor and a beta-blocker
a
a
h
hH. Ogata et al.
as a beneﬁcial effect on long-term survival of
MD patients with LV dysfunction. Moreover, the
ffect was greater in asymptomatic patients than
n symptomatic patients. Most DMD patients with
ardiomyopathy become symptomatic in their early
o middle teens and usually die of congestive heart
ailure within 2—3 years from the onset of symp-
oms [3]. In a previous study on survival of DMD
atients with congestive heart failure, of eight
atients who were 17.6± 3.9 years of age and were
reated with only digitalis and diuretics, three sur-
ived for 1 year, one survived for 4 years, and none
urvived for 5 years [17]. They died at 13.7—25.1
ears of age (mean age of death, 18.9± 4.2 years).
t has been reported that the mean survival period
or DMD patients with congestive heart failure was
6.0 months when LVEF had decreased to 30.1% and
hat the mean survival period was only 15.4 months
hen LVEF had decreased to 23.2% [16]. Eagle et
l. reported that NIV improved the rate of survival
o 25 years from 0 to 53%. Nevertheless, the mean
ge of survival in the presence of cardiomyopa-
hy is still only 16.9 years [5]. Most patients with
MD remain asymptomatic for many years in spite
f the progression of cardiac dysfunction because
f their wheelchair-bound state. Cardiac function
n DMD patients might therefore be NYHA III or IV
hen they initially experience cardiac symptoms.
n our experience, when the main therapy con-
isted of digitalis, diuretics, and catecholamines,
eart failure was aggravated rapidly and most
atients died within 2 years from the start of
herapy.
ACE inhibitors have been shown to remarkably
mprove the prognosis of patients with heart fail-
re [18—21]. Meta-analyses of randomized clinical
rials suggest that beta-blocker therapy has bene-
ts for survival in heart-failure patients. In these
rials, beta-blockers were conventionally admin-
stered with ACE inhibitors [6—11]. It has been
eported that the combination of a beta-blocker
nd an ACE inhibitor is beneﬁcial for survival of
atients with LV dysfunction [12—15]. Reports about
fﬁcacy of the combination of these two drugs for
reatment of heart failure in DMD patients are rare
16]. Results of controlled clinical trials on the efﬁ-
acy of the combination of an ACE inhibitor and a
eta-blocker for heart failure in DMD have not been
eported. In this study, the 5-year survival rate of
ll DMD patients with heart failure exceeded 90%.
oreover, some patients survived for more than 10n ACE inhibitor and a beta-blocker will remark-
bly improve the survival rate of DMD patients with
eart failure as has been shown for patients with
eart failure caused by other diseases.
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Reta-blockers and ACE inhibitors in Duchenne musc
arly use of a beta-blocker and an ACE
nhibitor
shikawa et al. reported the effectiveness of the
ombination of these two drugs in 11 DMD patients
ith symptomatic heart failure for relief of symp-
oms and decrease of activated neuroendocrine
evel during 5-year follow-up [16].
Long-term efﬁcacy of an ACE inhibitor and a
eta-blocker in DMD patients with reduced LVEF and
o symptoms has not been reported.
In this study, we classiﬁed patients as symp-
omatic (treatment group) or asymptomatic
prevention group) at the start of therapy and
nvestigated prognosis in the two groups. It has
een reported that beta-blockers are effective
or patients with NYHA class III or IV heart failure
aused by other diseases [9]. In this study, patients
n the treatment group achieved long-term survival
ompared with that previously reported. However,
n most of the patients in the treatment group,
eart failure gradually worsened about 7 years
fter the start of therapy. Patients with DMD are at
isk for developing heart failure. Early therapeutic
ntervention would be beneﬁcial for DMD patients
ith LV dysfunction even if they are asymptomatic
22]. We therefore started the treatment with an
CE inhibitor and a beta-blocker in asymptomatic
atients. The 5-year survival rate was maintained
t more than 90%. The survival rate of patients in
he treatment group decreased rapidly about 10
ears after starting medication. In the prevention
roup, the 10-year survival rate was 73% and 9
atients were free from symptoms of heart failure
ven more than 10 years after starting therapy.
tarting treatment with an ACE inhibitor and a
eta-blocker in the asymptomatic stage seems to
e effective for improving prognosis of patients
ith heart failure. A post-hoc analysis of results
f studies on LV dysfunction has shown that the
ombination of an ACE inhibitor and a beta-blocker
educes the risk of death in asymptomatic patients
ith heart failure [13]. In this study, criteria for
arly treatment to obtain the better prognosis in
symptomatic DMD patients with LV dysfunction
ere not identiﬁed. Long-term survival of patients
ith %FS > 19% tended to be better than that of
atients with %FS < 19%, but the difference was not
tatistically signiﬁcant.
ACC/AHA guidelines recommend that treatment
ith a beta-blocker should be initiated as soon
s LV dysfunction is diagnosed [15]. Duboc et al.
eported that early treatment with perindopril
onotherapy delayed the onset and progression
f LV dysfunction in DMD patients with normal
V function [23]. Further investigation is neededdystrophy 77
o determine the appropriate timing of early
reatment.
tudy limitations
his was a retrospective analysis at a single cen-
er, and there may be a patient selection bias.
he relationship between systolic cardiac param-
ters determined by ultrasound echocardiography
nd the timing of drug therapy to obtain longer
urvival was not identiﬁed in this study. Evalua-
ion of diastolic parameters by LV ﬁlling pattern in
chocardiography was not done sufﬁciently because
f deformity of the thoracic cavity or difﬁculty in
aintaining the left lateral decubitus position. Most
atients in this study used NIV constantly. It is well
nown that NIV has a favorable effect on heart
ailure [24]. It is expected that NIV contributes
o improvement in prognosis of DMD patients. We
ould not evaluate the effect of NIV and medication
ndependently in this study.
onclusion
he combination of an ACE inhibitor and a beta-
locker has a beneﬁcial effect on long-term survival
f DMD patients with heart failure. The treat-
ent was particularly effective for asymptomatic
atients with LV dysfunction. In DMD patients with
V dysfunction, treatment with the combination
f a beta-blocker and an ACE inhibitor should be
tarted as soon as possible.
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